Alzamend Neuro™ Secures New Licenses from USF to Treat Alzheimer’s Disease

Alzamend Neuro™ Secures New Licenses from USF to Treat Alzheimer’s Disease Cocrystal Lithium-Based Therapy, “LiProSal™” Targets the Reduction of Agitation in Patients with AD Salt Lake City, UT – (Globe Newswire – October 29, 2018) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it secured two new licenses from the University of…